PT  - JOURNAL ARTICLE
AU  - Dhar, Mahesh S
AU  - Marwal, Robin
AU  - Radhakrishnan, VS
AU  - Ponnusamy, Kalaiarasan
AU  - Jolly, Bani
AU  - Bhoyar, Rahul C.
AU  - Fatihi, Saman
AU  - Datta, Meena
AU  - Singh, Priyanka
AU  - Sharma, Uma
AU  - Ujjainia, Rajat
AU  - Naushin, Salwa
AU  - Bhateja, Nitin
AU  - Divakar, Mohit Kumar
AU  - Sardana, Viren
AU  - Singh, Manoj K
AU  - Imran, Mohamed
AU  - Senthivel, Vigneshwar
AU  - Maurya, Ranjeet
AU  - Jha, Neha
AU  - Mehta, Priyanka
AU  - Rophina, Mercy
AU  - Arvinden, VR
AU  - Chaudhary, Urmila
AU  - Thukral, Lipi
AU  - Pandey, Rajesh
AU  - Dash, Debasis
AU  - Faruq, Mohammed
AU  - Lall, Hemlata
AU  - Gogia, Hema
AU  - Madan, Preeti
AU  - Kulkarni, Sanket
AU  - Chauhan, Himanshu
AU  - Sengupta, Shantanu
AU  - Kabra, Sandhya
AU - The Indian SARS-CoV-2 Genomics Consortium (INSACOG)
AU  - Singh, Sujeet K
AU  - Agrawal, Anurag
AU  - Rakshit, Partha
TI  - Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India
AID  - 10.1101/2021.06.02.21258076
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.02.21258076
4099  - http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258076.short
4100  - http://medrxiv.org/content/early/2021/06/03/2021.06.02.21258076.full
AB  - In April 2021, after successfully enduring three waves of the SARS-CoV2 pandemic in 2020, and having reached population seropositivity of about 50%, Delhi, the national capital of India was overwhelmed by the fourth wave. Here, we trace viral, host, and social factors contributing to the scale and exponent of the fourth wave, when compared to preceding waves, in an epidemiological context. Genomic surveillance data from Delhi and surrounding states shows an early phase of the upsurge driven by the entry of the more transmissible B.1.1.7 variant of concern (VOC) into the region in January, with at least one B.1.1.7 super spreader event in February 2021, relatable to known mass gatherings over this period. This was followed by seeding of the B.1.617 VOC, which too is highly transmissible, with rapid expansion of B.1.617.2 sub-lineage outpacing all other lineages. This unprecedented growth of cases occurred in the background of high seropositivity, but with low median neutralizing antibody levels, in a serially sampled cohort. Vaccination breakthrough cases over this period were noted, disproportionately related to VOC in sequenced cases, but usually mild. We find that this surge of SARS-CoV2 infections in Delhi is best explained by the introduction of a new highly transmissible VOC, B.1.617.2, with likely immune-evasion properties; insufficient neutralizing immunity, despite high seropositivity; and social behavior that promoted transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport from Ministry of Health and Family Welfare, Council of Scientific and Industrial Research, and Department of Biotechnology, India, is acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SARSCoV2 genomic study was approved by the NCDC Ethics Review Committee vide approval 2020/NERC/14. The serology study was approved by the Institutional Human Ethics Committee of CSIRIGIB vide approval CSIR IGIB/IHEC/2019_20 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data is being continuously uploaded on the GISAID. https://www.gisaid.org/